Topical becocalcidiol for the treatment of psoriasis vulgaris: A randomized, placebo-controlled, double-blind, multicentre study

British Journal of Dermatology

Volumn 157, Issue 2, 2007, Pages 369-374

  Helfrich, Y R ^a   Kang, S ^a   Hamilton, T A ^a   Voorhees, J J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Becocalcidiol; Calcipotriol; Psoriasis vulgaris; Randomized controlled trial

Indexed keywords

BECOCALCIDIOL; CALCIPOTRIOL; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; APPLICATION SITE BURNING; ARTICLE; BODY SURFACE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PRURITUS; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SCORING SYSTEM; SIDE EFFECT; SKIN ALLERGY; STATISTICAL SIGNIFICANCE; URTICARIA;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34447530674     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08037.x     Document Type: Article

References (19)

1. Bikle DD, Ng D, Tu CL et al. Calcium- and vitamin D-regulated keratinocyte differentiation. Mol Cell Endocrinol 2001 177 : 161 71.
2. van de Kerkhof PCM. An update on vitamin D3 analogues in the treatment of psoriasis. Skin Pharmacol Appl Skin Physiol 1998 11 : 2 10.
3. Kang S, Yi S, Griffiths CEM et al. Calcipotriene-induced improvement in psoriasis is associated with reduced interleukin-8 and increased interleukin-10 levels within lesions. Br J Dermatol 1998 138 : 77 83.
4. Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D3 analogue (MC 903) in a double-blind study. Br J Dermatol 1988 119 : 223 30.
5. Dubertret L, Wallach D, Souteyrand P et al. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992 27 : 983 8.
6. Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995 32 : 67 72.
7. Harrington CI, Goldin D, Lovell CR et al. Comparative effects of two different calcipotriol (MC903) formulations vs. placebo in psoriasis vulgaris: a randomized, double-blind, placebo-controlled, parallel group multicentre study. J Eur Acad Dermatol Venereol 1996 6 : 152 8.
8. Kragballe K, Gjertsen BT, de Hoop D et al. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991 337 : 193 6.
9. Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993 129 : 74 6.
10. Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994 235 : 281 2.
11. Bourke JF, Mumford R, Whittaker P et al. The effects of topical calcipotriol on systemic calcium homeostasis in patients with chronic plaque psoriasis. J Am Acad Dermatol 1997 37 : 929 34.
12. Bleiker TO, Bourke JF, Mumford R et al. Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol. Br J Dermatol 1998 139 : 285 6.
13. Fogh K, Kragballe K. Recent developments in vitamin D analogs. Curr Pharm Des 2000 6 : 961 72.
14. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000 320 : 963 7.
15. Witman P. Topical therapies for localized psoriasis. Mayo Clin Proc 2001 76 : 943 9.
16. PDR Drug information for Dovonex ointment 0.005%. Physicians' Desk Reference. Available at : http://www.drugs.com/pro/dovonex-ointment.html (accessed 2 June 2007).
17. Plum LA, Prahl JM, Ma X et al. Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin D with an abbreviated side chain containing no hydroxyl. Proc Natl Acad Sci USA 2004 101 : 6900 4.
18. van de Kerkhof PCM, Kragballe K. Recommendations for the topical treatment of psoriasis. J Eur Acad Dermatol Venereol 2005 19 : 495 9.
19. Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004 15 : 14 22.